Asembia

Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health, discusses what's to come as a result of a "second wave" of biosimilars hitting the market.

Technology and automation within patient assistance programs can enhance the patient journey and assist pharmaceutical manufacturers at a lower cost, explained Josh Marsh, vice president of Sonexus at Cardinal Health.

At the first business session of Asembia 2023, Ray Tancredi, divisional vice president at Walgreens, provided updates to the 2023 specialty therapy pipeline.

In a panel at the 2023 Asembia Specialty Pharmacy Summit, speakers presented on the payer perspective regarding biosimilars, including that they feel comfortable preferring multiple biosimilars for the same reference product and are looking for interchangeability designations.

Panelists at the 2023 Asembia Specialty Pharmacy Summit discussed the myriad of ways that the drug pricing policies of the Inflation Reduction Act (IRA), such as inflation rebates and a redesign of Medicare Part D plans, will affect payers and manufacturers.

Several presentations at the 2023 Asembia Specialty Pharmacy Summit, held in Las Vegas, Nevada, from April 30 through May 4, will cover how to address health equity concerns in specialty pharmacy care, the expansion of the biosimilars market, and the impact of the Inflation Reduction Act (IRA) on the US health care system.

At Asembia 2023, there will be a call to action for participants to adjust their current business models and advocate for access to biosimilars with lower list costs, explained Julie Reed, executive director of the Biosimilars Forum.

The organizations that can take on 2-sided risk are usually bigger and that’s not always better for health care, said Jayson Slotnik, partner, Health Policy Strategies, Inc.

Alignment of incentives in the United States do not always support the use of biosimilars or other lower-cost alternatives, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.

As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents.

Many payers are not familiar with digital therapeutics, indicating the need for better education among payers, said Jayne Hornung, chief clinical officer, pharmacy, MMIT.

There are an increasing number of targeted therapies in oncology, but challenges around biomarker testing and treatment selection remain.

The logistics for storing chimeric antigen receptor (CAR) T-cell therapies remain a challenge, said Joel Wayment, vice president of operations for 3PL Services, Cardinal Health.

Across commercial insurance, Medicare, and Medicaid populations, oncology is the top category of spend, and the drug pipeline has increasing specific and complex therapies.

While 2023 is a big year with at least 7 adalimumab biosimilars expected to come to market, 2024 will be even more important because all the products will be on the market and formulary decisions can be made, said Sonia T. Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars at Cardinal Health.

Pediatric patients with asthma and their caregivers are faced with significant health and cost burdens, and biologics provide an opportunity to improve quality of life and asthma control, according to a panel of experts.

While CMS has started making changes to address health equity through policy and payment models, commercial plans are waiting to see the outcomes before they follow suit, said Jayson Slotnik, partner, Health Policy Strategies, Inc.

Biosimilar adoption can be accelerated or stymied depending on actions taken by the managed care space, explained Sonia Oskouei, PharmD, vice president, biosimilars, Cardinal Health, during a session at Asembia’s Specialty Pharmacy Summit.

David Skomo, and Nick Page, PharmD, of WellDyne offered their perspectives on recent developments in precision medicine at the 2022 Asembia Specialty Pharmacy Summit.

The impact that the adalimumab biosimilars will have in 2023 is going to depend on when they all get to market, said Doug Long, MBA, vice president, industry relations, IQVIA.

In a session at the 2022 Asembia Specialty Pharmacy Summit, Jayne Hornung, chief clinical officer at Managed Markets Insights & Technology (MMIT), outlined factors driving payer hesitation when it comes to covering prescription digital therapeutics.

Katharine Rimes, PharmD, and John Bosso, MD, discussed updates in management of chronic rhinosinusitis with nasal polyps at the 2022 Asembia Specialty Pharmacy Summit.

Coverage, equity, and value-based payments are critical areas of focus for the Biden administration’s health care agenda leading up to the midterm elections, according to 3 experts from Avalere.

Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.

Addressing rural care is a way of addressing health inequities, and the Biden administration’s recent investment in rural care reflects its commitment to addressing health equity, said Ryan Urgo, MPAP, managing director, health policy, Avalere.

Panelists discussed results of a survey conducted among 171 benefits leaders representing more than 40 million covered lives.

The pandemic drove telehealth usage, but it has challenges that might prevent doctors from prescribing new therapies, said Doug Long, MBA, vice president, industry relations, IQVIA.

Adam Fein, PhD, of Drug Channels Institute, and Doug Long of IQVIA discussed trends in the specialty pharmacy market in the United States.

Representatives from employers, pharmacy benefit managers, and others discussed methods of improving pharmacy access and affordability in health plans.

Value-based payments were a benefit during the pandemic, but it remains to be seen if patients are interested in keeping those changes in care delivery as the pandemic recedes, said Jayson Slotnik, partner, Health Policy Strategies, Inc.